SAN DIEGO--(BUSINESS WIRE)--
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today announced that it has sponsored the 10th Annual LD Micro Main Event Conference, which will be held on Tuesday, December 5 to Thursday December 7, 2017. Innovus Pharma will have a booth at the conference and will be available to meet with investors or potential partners. The event will be take place at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Innovus Pharma senior leadership and management will be attending the conference and anticipate meeting with investors and/or potential partners throughout the day to talk about the recent launch of their flagship product, FlutiCare® for nasal allergy relief, as well as their other products along with the Company’s progress and continue growth. Investors or potential partners wishing to schedule a meeting should contact Chris Lahiji President, LD Micro 408-457-1042 or James S. Painter at Emergent Markets LLC, the Company’s Investor Relations firm at 407-340-0226 or [email protected].
FlutiCare® contains the most prescribed nasal steroid active pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare® in over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media platform and through its extensive online channels and distributors, including www.FlutiCare.com, Amazon.com, and Walmart.com. As a second phase of its launch, Innovus Pharma will launch FlutiCare® to large retail stores in the near future.
FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare® will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.
FlutiCare® allergy relief joins the growing Innovus Pharma product family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers. FlutiCare® becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.
About FlutiCare®
FlutiCare® is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare® can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.
FlutiCare® contains the nasal steroid API that is physician recommended and consumer preferred
- #1 form used by patients;
- #1 nasal steroid active prescribed by physicians;
- Familiar to patients, comfort of a known & trusted medicine;
- Engrained in patients’ allergy management; and
- Effective and safe.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which the Company markets directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through its on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s need for additional equity or debt financing, to receive applicable regulatory approval for its products, successfully commercialize of its products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
*Flonase® is a registered trademark of GSK and ClariSpray® is a registered trademark of Bayer.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171120005326/en/
